Galera Therapeutics, Inc.
OOTC:GRTXD18.99
USD
+3.37
(+21.57%)
CIK
1563577
ISIN
US36338D2071
CUSIP
36338D207
Return %
Stock
S&P 500
1Y
312.83
14.20
3Y
-95.74
81.12
5Y
-98.85
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- John Mel Sorensen
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Malvern United States
- CIK
- 0001563577
- Website
- galeratx.com
- Similar Companies
- Business
- Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted small-molecule therapeutics designed to transform radiotherapy in cancer treatment and address severe cancer-related toxicities. The company operates within the biotechnology and pharmaceutical sectors, primarily serving oncology healthcare providers, specialized cancer centers, and cancer patients across the United States. Galera Therapeutics' historical and core proprietary product portfolio centers on small-molecule superoxide dismutase (SOD) mimetics and novel enzyme inhibitors, comprising: avasopasem manganese (GC4419), a selective, synthetic small-molecule dismutase mimetic developed to reduce the incidence and duration of radiotherapy-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer; rucosopasem manganese (GC4711), a second-generation dismutase mimetic designed to selectively convert superoxide to hydrogen peroxide to augment the anti-tumor efficacy of stereotactic body radiation therapy in non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer; and pan-nitric oxide synthase (NOS) inhibitors investigated for therapeutic application in advanced oncologic conditions, including breast cancer. Founded in 2012 and headquartered in Malvern, Pennsylvania, the company conducts its clinical and operational activities in the United States. In recent developments, Galera Therapeutics executed major strategic, operational, and structural transformations following regulatory and clinical milestones. After receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for avasopasem manganese, the company implemented strategic reprioritizations and workforce rationalizations. In October 2025, Galera completed the divestiture and asset transfer of its legacy dismutase mimetic programs, including avasopasem and rucosopasem, to Biossil, Inc. To optimize its capital structure, the company executed a 1-for-200 reverse stock split, trading on the OTCQB venture market under the ticker symbol GRTXD. In August 2026, Galera Therapeutics completed an all-stock merger with Obsidian Therapeutics, Inc., transitioning Galera into an operating subsidiary within the combined biopharmaceutical entity, which operates under the Obsidian Therapeutics name, trades on the Nasdaq under the ticker symbol OBX, and is capitalized by an oversubscribed 350 million dollar concurrent private placement financing to advance engineered cell therapies and oncology pipelines.